Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, announces that it is presenting results of a novel
Quality Assessment Product (“
QAP™”) for supporting
patient diagnosis and tissue analysis relating to infection with
the Herpes Simplex Virus (“
HSV”) at the European
Meeting on Molecular Diagnostics (“
EMMD”) taking
place in Noordwijk, The Netherlands, October 9 to 11, 2024.
At EMMD, Microbix will interact with key opinion
leaders, collaborators, and customers that create and utilize the
available assays to diagnose, screen, and direct treatment of HSV,
many other infectious diseases, and other conditions such as
cancers. Microbix will also be attending multiple scientific and
clinical care lectures and discussions that are directly pertinent
to its ever-growing portfolio of QAPs that help ensure the accuracy
of molecular (i.e., “PCR”) tests and their
workflows.
Also at EMMD, Microbix will present its poster
titled “FFPE HSV-1 and HSV-2 simulated tissue sections mounted on
slides for use as prospective quality controls in IHC and qPCR
workflows.” The poster reviews the performance of a novel (RUO) QAP
to support PCR-based detection of HSV and immunohistochemical
analysis of Formalin-Fixed and Paraffin-Embedded
(“FFPE”) tissue samples. Following presentation of
the poster on the afternoon of October 9th, it will be made
available at https://microbix.com.
In spite of efforts to detect, treat, and
prevent the spread of HSV, it is estimated that over half of all
people worldwide are chronically infected with a strain of this
virus. Emerging research is also establishing that chronic
infection with HSV is a risk factor for, and can lead to, severe
conditions like esophagitis, hepatitis, pneumonia, encephalitis,
cancer, and neurodegenerative disorders. More widespread diagnosis
of HSV and detailed analysis of infected tissues may therefore be a
route to prevention of the serious health consequences that can
result from HSV infections. Microbix is pleased to support the more
widespread use of such testing by helping to ensure its quality and
accuracy.
Pavel Zhelev, Microbix’s Director of Product
Management and a co-author of the poster commented, “We believe our
latest QAP is the first test-control that is fully consistent and
reproducible for supporting both molecular and immunohistochemical
analyses of HSV-infected FFPE tissue samples. We are pleased to
support cutting-edge science in this field of chronic infection and
resulting genetic damage – building from our portfolio of
industry-leading test-controls in liquid, Copan FLOQSwab, and FFPE
formats.”
Microbix gratefully acknowledges two external
collaborators on this work, namely Sunnybrook Research Institute
(Canada), and QuidelOrtho Corporation (United States).
Purchase enquiries for Microbix QAPs can be
e-mailed to customer.service@microbix.com.
About Microbix Biosystems
Inc.Microbix Biosystems Inc. creates proprietary
biological products for human health, with over 100 skilled
employees and sales now targeting C$ 2.0 million per month. It
makes and exports a wide range of critical ingredients and devices
for the global diagnostics industry, notably antigens for
immunoassays and its laboratory quality assessment products (QAPs™)
that support clinical lab proficiency testing, enable assay
development and validation, or help ensure the quality of clinical
diagnostic workflows. Its antigens drive the antibody tests of
approximately 100 diagnostics makers, while QAPs are sold to
clinical lab accreditation organizations, diagnostics companies,
and clinical labs. Microbix QAPs are now available in over 30
countries, supported by a network of international distributors.
Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered,
Australian TGA registered, Health Canada establishment licensed,
and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably Kinlytic® urokinase, a biologic
thrombolytic drug used to treat blood clots, and reagents or media
to support molecular diagnostic testing (e.g., its DxTM™ for
patient-sample collection). Microbix is traded on the TSX and
OTCQX, and headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of EMMD, the
Poster, the HSV QAPs, or their relevance, Microbix’s or others’
products or services, business and business results, goals or
outlook, risks associated with financial results and stability,
development projects such as those referenced in its presentations,
regulatory compliance and approvals, sales to foreign
jurisdictions, engineering and construction, production (including
control over costs, quality, quantity or timeliness of delivery),
currency exchange rates, maintaining adequate working capital or
raising new capital on acceptable terms or at all, and other
similar statements about anticipated future events, conditions or
results that are not historical facts. These statements reflect
management’s current estimates, beliefs, intentions, and
expectations; they are not guarantees of future performance.
Microbix cautions that all forward-looking information is
inherently uncertain and actual performance may be affected by a
number of material factors, many of which are beyond its control.
Accordingly, actual future events, conditions and results may
differ materially from the estimates, beliefs, intentions, and
expectations expressed or implied in the forward-looking
information. All statements are made as of the date of this news
release and represent Microbix’s judgement as of the date of this
new release, and it is under no obligation to update or alter any
forward-looking information.
Please visit https://microbix.com or www.sedar.com
for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome,CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793ir@microbix.com |
|
|
|
|
|
Copyright © 2024 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix
Biosystems Inc.Copan®, FLOQ®, and FLOQSwab® are trademarks of Copan
Italia S.p.A.Other companies’ names or products are protected by
their respective trademarks.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Dec 2023 to Dec 2024